Paroxysmal Nocturnal Haemoglobinuria | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

1,585 results for “Paroxysmal Nocturnal Haemoglobinuria”

Trials

View all 1356 →

Study of Global Coagulation Tests in Patients With Paroxysmal Nocturnal Haemoglobinuria

60 participants · First posted Nov 25, 2009

Active, not recruiting

Real-life Treatment Outcomes of Ravulizumab in PNH

64 participants · First posted Oct 9, 2024

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

1 participants · First posted Oct 30, 2015

Drugs

View all 12 →

C3b recognition inhibitors (oral, paroxysmal nocturnal hemoglobinuria)

Pegcetacoplan(Empaveli, Syfovre, Aspaveli)

Conditions: Geographic Atrophy Secondary to Age-related Macular Degeneration, Paroxysmal Nocturnal Haemoglobinuria (PNH)

Rx

Ravulizumab(Ultomiris)

Conditions: Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis +2 more

Organizations

Oncternal Therapeutics

United States

News

View all 216 →

Roche's PiaSky Approved in EU as First Monthly Self-Administered Treatment for Paroxysmal Nocturnal Haemoglobinuria

AstraZeneca's Oral Drug Danicopan Receives CHMP Backing for PNH-Related Anaemia Treatment

FDA Blocks Approval of AstraZeneca's Ultomiris for Neuromyelitis Optica Spectrum Disorder

Page 1 of 159